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Egr1A growing body of evidence suggests that the circadian molecular system is involved in the pathogenic and
therapeutic mechanisms underlying bipolar disorders. Lithium, a representative mood stabilizer, has been
reported to induce the Period2 (PER2) gene; however, the underlying molecular mechanisms require further
study.We found that lithium upregulated PER2 expression at the transcriptional level in neuronally differentiated
SH-SY5Y human neuroblastoma cells. Promoter reporter analyses using serial deletions of the PER2 promoter
revealed that two early growth response 1 (Egr1)-binding sites (EBS) between positions −180 and −100 are
required for maximal activation of the PER2 promoter by lithium. Ectopic expression of Egr1 enhanced lithium-
induced PER2 promoter activity, while a point mutation in EBS abolished it. Electrophoretic mobility shift assays
and chromatin immunoprecipitation indicated that Egr1 bound directly to the PER2 promoter. Stimulation of the
extracellular-signal regulated kinase (ERK)1/2/Elk1 pathway by lithium was functionally linked to PER2 expres-
sion through Egr1 induction, and lithium-induced PER2 expression was strongly attenuated by depletion of
Egr1 by siRNA. Lithium also upregulated the expression of Per2 and Egr1 in mouse frontal cortex. Induction of
Per2 by lithium was attenuated in Egr1−/− mice. In conclusion, lithium stimulates PER2 transcription through
the ERK/Elk1/Egr1 pathway in neuronal cells, indicating a connection between the ERK-Egr1 pathway and a
circadian gene system in the mechanism of action of lithium.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
The circadian clock is an intrinsic oscillation system that controls
daily physiological and behavioral processes with ~24 h periodicity.
A highly specialized master pacemaker of the mammalian circadian
clock resides in the suprachiasmatic nucleus (SCN) of the anterior
hypothalamus, which receives photic input from the retina and con-
veys timing information to the entire organism [1]. Outside the SCN,
peripheral tissue clocks also exist and they are either synchronized
with the SCN or independent from the master clock [2]. Peripheral
circadian genes have been widely implicated in non-circadian roles
including cell survival, proliferation, and metabolism [3,4]. Circadian
genes are also widely expressed throughout the brain, and, in the
forebrain regions, they are involved in the regulation of mood, anxiety,
and cognition [5–11].Sciences, Konkuk University, 1
c of Korea. Tel.: +82 2 2030
konkuk.ac.kr (S.Y. Shin).
rights reserved.Oscillation of circadian gene expression is generated via inter-
connected transcriptional–translational feedback loops [1,12–14]. A
positive feedback loop is formed by two bHLH-PAS domain proteins,
brain and muscle aryl hydrocarbon receptor nuclear translocator-like
protein 1 (BMAL1) and circadian locomotor output cycles kaput
(CLOCK), that heterodimerize and activate a number of clock genes,
including period1 (PER1), PER2, cryptochrome1 (CRY1), and CRY2 in an
E-box-dependent manner [15,16]. As a negative feedback loop, PER
and CRY accumulate in the cytosol and then translocate to the nucleus
and inhibit their own and other E-box-regulated promoters [16,17].
Various kinases, including glycogen synthase kinase-3β (GSK-3β),
mitogen-activated protein kinase (MAPK), casein kinase (CK) I, and
CKII, are involved in translational modiﬁcations of clock proteins regu-
lating protein stability and translocation [18].
Involvement of the circadian system in bipolar disorder has been
reported. Disturbances in the sleep–wake cycle are frequently associated
with mood episodes, and bipolar patients may also have abnormal
rhythms in body temperature, blood pressure, and melatonin secretion
[9,10,19,20]. Genetic studies have examined variants in circadian genes
including PER2, PER3, BMAL1, CLOCK, and retinoid REV-ERBα as potential
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inconclusive [21–24].
Lithium is still the ﬁrst-line mood stabilizer for the treatment of
bipolar disorder [25,26]. Research on the molecular-genetic mecha-
nisms of lithium has been used to understand the therapeutic mecha-
nisms of bipolar disorder. For example, the International Consortium
on Lithium Genetics (ConLiGen) has been formed to investigate the
pharmacogenetic underpinnings of bipolar disorder [27]. Lithium affects
circadian systems, prolonging the circadian period of locomotor activity
and body temperature rhythm in humans and mice [28,29]. The effects
of lithium on circadian genes have been investigated, and PER2 has
been suggested to be lithium-responsive. Lithium induces increased ex-
pression and a prolonged period of Per2 inmouseﬁbroblast NIH3T3 cells
[30,31], and cells from PER2::LUC knock-in mice [29,32]. Microarray
analysis revealed that chronic lithium treatment induces upregulation
of Per2 mRNA in mouse brain [33]. A recent report suggested that
lithium upregulates Per2 at the transcriptional level [29]. Although
lithium-induced lengthening and upregulation of PER2 have been
reported to be associated with changes in the phosphorylation of PER2
through GSK-3β [30], the detailed mechanisms of lithium's effects on
Per2 transcription are not yet fully understood. For example, the
lithium-induced increase in Per2 expression does not co-occur with a
preceding increase in Clock and Bmal1, representative transcriptional
activators of Per2 via the E-box [31].
In the present study, we found that Egr1-binding sites in the
PER2 promoter are required for lithium-responsive PER2 induction.
An in vitro study revealed that lithium upregulated PER2 transcription
via an extracellular-signal regulated kinase 1/2 (ERK1/2)-Elk1-mediated
Egr1 signaling pathway. We conﬁrmed the role of Egr1 in lithium-
induced Per2 expression using Egr1−/− mice. These ﬁndings reveal
a novel mechanism regarding the effects of lithium on circadian
genes.
2. Materials and methods
2.1. Materials and methods
Lithium chloride (LiCl) was purchased from Sigma-Aldrich
(Saint Louis, MO, USA). U0126, SB203580, and SP600125 were
purchased from Calbiochem (San Diego, CA, USA). Antibodies against
phospho-ERK1/2 (Thr202/Tyr204), phospho-JNK1/2 (Thr183/Tyr185),
phospho-p38 (Thr180/Tyr182), and phospho-Elk1 (Ser383) (Cell Sig-
naling Technology, Beverly, MA, USA), Egr1, β-actin, GAPDH (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), and PER2 (Abcam, Cambridge,
UK) were used. The ﬁreﬂy and Renilla Dual-Glo Luciferase Assay System
was purchased from Promega (Madison, WI, USA).
2.2. Neuronal differentiation of SH-SY5Y cells
SH-SY5Y cells (Cell Line Service, Eppelheim, Germany) were
maintained in DMEM:Ham's F12 (1:1 mixture), supplemented with
2 mM L-glutamine and 10% fetal bovine serum (FBS; Hyclone,
Logan, UT, USA). For differentiation, SH-SY5Y cells were treated
with 50 μM all-trans retinoic acid (RA; Sigma-Aldrich) for 5 days as
described previously [34].
2.3. Animals and drug treatment
Male C57BL6 mice and Egr1−/−mice (20–25 g) were grouped and
maintained on a 12/12-h light/dark cycle with food and water freely
available. Egr1−/− mice developed on a C57BL6 background were from
Dr. Jeffrey Milbrandt (Washington University, St. Louis, MO, USA) and
have been described elsewhere [35,36]. Animals were treated in accor-
dance with the NIH Guide for the Care and Use of Laboratory Animals.
Lithium was dissolved in vehicle (0.9% saline). Each mouse received an
intraperitoneal (i.p.) injection of lithium or vehicle in a volume of100 μL. Two hours after injection, mice were decapitated to acquire
brain tissues. The dose of lithium (150 mg/kg) was determined based
on previous studies [37,38]. A dose of 150 mg/kg has been reported to
inhibit amphetamine-induced hyperlocomotion in mice [39–42], which
mimics the therapeutic effects of lithium. Following systemic adminis-
tration of lithium, serum and brain levels of the drug were found to be
within the accepted therapeutic range for rats and mice [39,43].
2.4. Plasmids
A full-length EGR1 promoter reporter plasmid, pEgr1-Luc (−780/
+1), was provided by Dr. H. Eibel (Department of Orthopedic Surgery,
University of TübingenMedical Center, Germany) and is described else-
where [44]. pFA2-Elk1, which encodes a fusion protein consisting of the
yeast Gal4 DNA-binding domain (amino acids 1–147) and the activa-
tion domain of Elk1 (amino acids 307–427), and plasmid pFR-Luc,
which containsﬁve Gal4-binding element repeats upstreamof the lucif-
erase gene, were purchased from Stratagene (La Jolla, CA, USA). An Elk1
expression plasmid (pCMV/ﬂagElk1) was a gift from Dr. A. Sharrocks
(Faculty of Life Sciences, University of Manchester, UK). Plasmids
expressing dominant negative (dn)-MEK1 (pCGN1/MEK DN), dn-Erk2
(pHA-Erk2 K52R), dn-JNK1 (pSRα/HA-JNK T183A/Y185F), and dn-p38
kinase (pCDNA3/ﬂag-p38 T180A/Y182F) were provided by Dr. D.S.
Min (Department of Molecular Biology, College of Natural Science,
Pusan National University, Korea). The pCDNA3.1/Egr1 plasmid, which
expresses dominant-active (da)-Egr1(I293F), was generated as described
previously [45].
2.5. Western blot analysis
Total cell lysates were prepared, separated, and transferred to nitro-
cellulose ﬁlters as described previously [36]. Signals were developed
using an enhanced chemiluminescence detection system (GE Life
Sciences, Piscataway, NJ, USA). For brain tissue samples, the mice were
decapitated at the designated time after intraperitoneal injection
of lithium and/or SL327; the frontal cortex was dissected and homoge-
nized, and the immunoblot analysis was performed as described previ-
ously [46].
2.6. Immunoﬂuorescence microscopy
RA-treated SH-SY5Y (RA-SH-SY5Y) cells plated on coverslips were
either left untreated or treated with 20 mM LiCl for 12 h. The dose of
20 mM lithium used in the in vitro experimentwas based on a previous
study showing that lithium at that dose activated MAPK and inhibited
GSK-3β in SH-SY5Y cells, with no evidence of cellular toxicity [47].
Then they were ﬁxed and permeabilized as described previously [48].
The samples were co-stained with mouse anti-microtubule-associated
protein 2 (MAP2, 1:100) for neuronal marker and rabbit anti-PER2
(1:200) antibodies for 90 min at room temperature and then incubated
for 30 min with Alexa-Fluor 488-conjugated anti-mouse and Alexa-
Fluor 555-conjugated anti-rabbit secondary antibodies, yielding green
and red signals, respectively. Nuclear DNA was stained with 1 μg/mL
Hoechst 33258 (blue signal) for 10 min. The labeled cells were exam-
ined using an EVOSf1 ﬂuorescence microscope (Advance Microscopy
Group, Bothell, WA, USA).
2.7. Northern blot analysis
For each sample, 10 μg total RNA was electrophoresed on a
formaldehyde/agarose gel and transferred to a Hybond N+ nylon
membrane (Amersham Pharmacia Biotech). Northern blotting
was performed with a [γ-32P]dCTP-labeled human PER2 cDNA
probe, followed by hybridization with a glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) cDNA probe.
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Cells were treated with 20 mM LiCl for different periods of time.
Total RNA was extracted using a Trizol RNA extraction kit (Invitrogen,
Carlsbad, CA, USA). First-strand cDNA was synthesized using an
iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). Quantitative
real-time PCR was performed using an icycler iQ system (Bio-Rad)
with a TaqMan-iQ Supermix Kit (Bio-Rad). The TaqMan ﬂurogenic
probes and PCR primers for PER2 and GAPDH were designed by
Metabion Int. (Martinsried, Germany). The relative changes in PER2
mRNA levels were normalized to GAPDH mRNA in the same samples.
For RT-PCR analysis, the PCR conditions for all primers were as follows:
hold for 4 min at 95 °C, followed by 30 cycles consisting of denaturation
at 95 °C (30 s), annealing at 65 °C (30 s), and elongation at 72 °C (30 s).
The ampliﬁed productswere subjected to 1% agarose gel electrophoresis.
RNA from themouse frontal cortical tissue was detected using real-time
PCR using an ABI PRISM 7000 instrument (Applied Biosystems, Foster
City, CA, USA), and a SYBRGreen PCR real-time PCRMasterMix (Toyobo,
Osaka, Japan)was used according to themanufacturer's instructions. The
reaction was ﬁrst incubated at 50 °C for 2 min, then at 95 °C for 10 min,
followed by 35 cycles of 95 °C for 15 s and 60 °C for 1 min. Each
gene-speciﬁc PCR was performed in triplicate. The relative changes in
Per2mRNA levels were normalized for β-actinmRNA in the same sam-
ples. The primers are summarized in Table 1.2.9. Construction and site-directed mutagenesis of the human PER2
promoter reporter
A PER2 promoter fragment spanning nucleotides −998 to +50
was synthesized from human genomic DNA (Promega) by PCR using
the primers 5′-TCTCCCTAGTGATGCGCTTG-3′ (forward primer;−998F)
and 5′-CAGCAGCCCAAGGAACTT-3′ (reverse primer; +50R). The
products were ligated into the KpnI and BglII sites of the pGL4-basic
vector (Promega), yielding pPer2-Luc (−998/+50). A series of deletion
constructs of human PER2 promoter fragments was synthesized by PCR
using the pPer2-Luc (−998/+50) plasmid as the template. For-
ward primer sequences were 5′-GGGCGTAGTGAATGGAAGGCG-3′
(−500/+50), 5′-CAGATGAGACGGAGTCGCGGC-3′ (−300/+50),
5′-ATACGTGCAGCTGTGGGCGGC-3′ (−180/+50), and 5′-GGCTGACGCG
GGCGCGGC-3′ (−100/+50). One reverse primer, +50R, was used toTable 1
Primers for quantitative real-time PCR and reverse transcription-PCR (RT-PCR).
Real-time PCR (human, TaqMan)
hPER2 Forward 5′-CCACTGCCATTACTA CTTG-3′
Reverse 5′-GGACTTCAATTTTCTGTTCTTTC-3′
TaqManTM ﬂuorogenic probe 5′-FAM-AGCCAAGTGAACGAA CTG
CCC-BHQ-3′
hGAPDH Forward 5′-TCGACAGTCAGCCGCATCTTC-3′
Reverse 5′-CGCCCAATACGACCAAATCCG-3′
TaqManTM ﬂuorogenic probe 5′-Yakima Yellow TM-CGTCGCCAGC
CGAGCCACATCGC-BHQ-3′
RT-PCR (human)
hPER2 Forward 5′-CCACGAGAATGAAATCCGCT-3′
Reverse 5′-CCTCCCAATGATGAAGGAGA-3′
hGAPDH Forward 5′-ACCCACTCCTCCACCTTTG-3′
Reverse 5′-CTCTTGTGCTCTTGCTGGG-3′
Real-time PCR (mouse, SYBR green)
mPer2 Forward 5′-GGCTTCACCATGCCTGTTGT-3′
Reverse 5′-GGAGTTATTTCGGAGGCAAGTGT-3′
mEgr1 Forward 5′-AGCGAACAACCTATGAGCA-3′
Reverse 5′-TCGTTTGGCTGGGATAACTC-3′
mActin Forward 5′-CTTCCTCCCTGGAGAAGAGC-3′
Reverse 5′-AAGGAAGGCTGGAAAAGAGC-3′generate all constructs. Ampliﬁed PCR products were ligated into the
KpnI and BglII sites of the pGL4-basic vector. Site-speciﬁc mutations in
the Egr1-binding sites within the PER2 promoter were made with the
QuickChangeII Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA),
using pPer2-Luc (−180/+50) as template. Primer sequences used to
generate point mutations were 5′-GTGGGCggCGG-3′ for disruption of
the Egr1 binding site (lower-case letters are mutated bases). All muta-
tions were veriﬁed by DNA sequencing.
2.10. Luciferase reporter assay
SH-SY5Y cells were seeded into 12-well plates and transfected
with 0.5 μg promoter reporter construct using Lipofectamine 2000
(Invitrogen). For promoter reporter assay, cells were transfected
with 0.2 μg luciferase reporter constructs. For Elk1 trans-acting activity,
cells were cotransfected with 50 ng trans-activator plasmid (pFA2-Elk1)
and 0.5 μg reporter plasmid (pFR-Luc). Tomonitor transfection efﬁciency,
50 ng pRL-null plasmid encoding Renilla luciferase was included in all
samples. Where indicated, 0.2 μg mammalian expression vector was
also included. At 24 h post-transfection, the levels of ﬁreﬂy and Renilla
luciferase activity were measured sequentially from a single sample
using the Dual-Glo Luciferase Assay System with a luminometer (Centro
LB960; Berthold Tech, Bad Wildbad, Germany).
2.11. Chromatin immunoprecipitation (ChIP)
RA-SH-SY5Y cells treated with 20 mM LiCl were cross-linked, lysed,
and chromatin immunoprecipitated using rabbit anti-Egr1 antibody or
normal rabbit IgG as described previously [36]. The precipitated DNA
was analyzed by standard RT-PCR methods. The following promoter-
speciﬁc primers were used for PCR: 5′-GCTGAGGGGATACGTGCA-3′
(target region; forward primer, −189/−172), 5′-GCGGTTACGTAAGC
CGCA-3′ (target region; reverse primer, −53/−36), 5′-CGGTAAGGT
GTGGATGAG-3′ (off-target region; forward primer, −1891/−1874),
and 5′-GACACCTCGACACACTCC-3′ (off-target region; reverse primer,
−1718/−1701).
2.12. Expression of siRNA
Short hairpin RNA (shRNA) plasmids expressing Egr1 siRNA or
scrambled control siRNA have been described elsewhere [36,49].
2.13. Statistical analyses
Each experiment was repeated at least three times. Data are
expressed as means ± standard errors. Statistical comparisons were
performed using Student's t-test and a one-way or two-way analysis
of variance (ANOVA) followed by a post hoc LSD test. P-values b0.05
were considered statistically signiﬁcant. All tests were performed
using the SPSS software (ver. 19.0 forWindows; IBM SPSS Inc., Chicago,
IL, USA).
3. Results
3.1. Lithium increases PER2 protein and mRNA in RA-SH-SY5Y cells
We ﬁrst determined the effect of lithium on the amount of PER2 in
neuronally differentiated SH-SY5Y (RA-SH-SY5Y) cells. The PER2protein
level increased in a dose-dependent manner following lithium stimula-
tion for 12 h (Fig. 1A). Lithium is known to inhibit GSK-3β [50]. GSK-3β
was reported to phosphorylate Per2 and promote the nuclear entry of
Per2, which inhibits Bmal-Clock complex-mediated Per2 transcription
in serum-shocked mouse NIH3T3 cells [30]. Although lithium-induced
lengthening of the circadian period and upregulation of Per2 may be
associated with changes in GSK-3β phosphorylation of Per2 [30], direct
involvement of GSK-3β in the regulation of PER2 transcription has not
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of lithium on PER2 transcription are not understood. In RA-SH-SY5Y
cells, to address whether lithium increases PER2 amount through the
inhibition of GSK-3β, we tested the effect of a GSK-3β inhibitor on
PER2 protein level. Treatment with the selective GSK-3β inhibitor,
SB212763, alone did not affect the amount of PER2 (Fig. 1A), suggesting
that lithium-induced increase in the amount of PER2 proteinmay be in-
dependent of the effect of GSK-3β in RA-SH-SY5Y cells. In a time-course
analysis, an increase in PER2 protein was evident within 6 h and the
maximal level was reached at 12 h, after which the level declined
(Fig. 1B). In immunoﬂuorescence staining, PER2 proteinswere detected
faintly in unstimulated cells, but stained strongly in the nuclei of cells
12 h after lithium treatment (Fig. 1C). To investigate whether increases
in PER2protein induced by lithiumoccur at themRNA level,we analyzed
PER2 mRNA levels using RT-PCR (Fig. 1D) and Northern blot (Fig. 1E)
analyses. Real-time PCR using the TaqMan ﬂurogenic probes showed
that lithium signiﬁcantly increased PER2 mRNA levels by 1.7 and
3.2-fold after 6 h (P b 0.05) and 9 h (P b 0.05), respectively comparedA
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3.2. Egr1-binding sequences within the PER2 promoter are critical for
lithium-induced PER2 transcription
To investigate whether the lithium-induced expression of PER2
mRNA is regulated by a transcriptional process, we isolated a
1047 bp genomic fragment encompassing the human PER2 promoter
(−938/+50), inserted it upstream of a luciferase reporter gene, and
then tested responsiveness to lithium treatment. Lithium signiﬁcantly
increased PER2 promoter activity (Fig. 2A). To identify the region respon-
sible that mediates the responsiveness of the PER2 gene to lithium, pro-
gressively deleted genome fragments encompassing the PER2 promoter
were constructed and transfected into SH-SY5Y cells. Basal promoter
reporter activitywas enhanced by deletion to−500, and further deletion
resulted in progressive attenuation of basal reporter activity (Fig. 2A),
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Then, 48 h later, the cells were treated with 20 mM LiCl for 8 h, and luciferase activities were measured. The data shown are the means ± SD of three independent experiments
performed in triplicate. *, P b 0.05 (n = 9). (B) Egr1 and SP1 binding motifs within the PER2 promoter region. (C) SH-SY5Y cells were transiently cotransfected with 0.2 μg human
PER2 promoter reporter construct, pPer2-Luc (−180/+50), and different concentrations of expression plasmids for EGR1 or SP1, along with 50 ng expression plasmid for Renilla
luciferase (pRL-null) to normalize transfection efﬁciency. The data shown are the means ± SD of three independent experiments performed in triplicate. *, P b 0.05 vs. control
(n = 9). (D) SH-SY5Y cells were transiently cotransfected with 0.2 μg wild-type (WT) or site-speciﬁc mutant construct for EGR1 (mtEgr1) derived from the pPer2-Luc (−180/+50).
Then, 48 h later, the cells were treated with 20 mM LiCl for 8 h, and luciferase activities were measured. The data shown are the means ± SD of three independent experiments
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BMAL1 and CLOCK, is essential for PER2 transcription [12,16]. Interesting-
ly, lithium stimulated the −180/+50 construct lacking the E-box-like
sequence; although basal promoter activity was suppressed, the increase
(~1.6-fold)was similar compared to the−300/+50 construct. However,
deletion of nucleotides −180 to −101 resulted in complete loss of
lithium inducibility. Thus, we suggest that the proximal region between
nucleotides −180 and −100 of the PER2 promoter contains cis-acting
regulatory element(s) responsive to lithium. To test this, we analyzed
the human PER2 promoter sequences spanning −180 to −100 using
the program MatInspector (http://www.genomatix.de/) and found two
overlapping binding motifs for EGR1 and speciﬁcity protein 1 (SP1)
(Fig. 2B).3.3. EGR1 transactivates the PER2 promoter
To assess whether EGR1 or SP1 activates the human PER2 promoter,
we cotransfected the pPer2-Luc (−182/+50) promoter construct and
an expression plasmid for EGR1 or SP1 into SH-SY5Y cells. Ectopic
expression of EGR1, but not SP1, enhanced lithium-induced promoter
reporter activity (Fig. 2C). Notably, even in the absence of lithiumtreatment, EGR1 caused basal reporter activity to increase as the
amount of transfected DNA increased.
To characterize whether the putative EGR1-binding sequences were
responsible for the stimulation of the PER2 gene promoter by lithium,
two core sequences of the EGR1 binding site on the promoter weremu-
tated (mtEgr1; GCGG → GCTT) within the context of the −180/+50
construct by site-directed mutagenesis. Disruption of EGR1 sites led to
a complete loss in lithium-induced reporter activity (Fig. 2D), indicating
that EGR1-binding sequences located at −180/−100 were key for
lithium-induced PER2 gene transcription.3.4. EGR1 directly binds a consensus sequence within the PER2 promoter
To investigate whether EGR1 binds directly to the putative EGR1-
binding sequence in the PER2 promoter in vivo, a ChIP assay was
performed. Cross-linked SH-SY5Y cells were immunoprecipitated with
rabbit anti-Egr1 antibody or normal rabbit IgG. The resulting immuno-
precipitates were analyzed by PCR assays using primers ﬂanking the
EGR1-binding sequences (−189 to −38) of the PER2 promoter. A
noticeable increase in the intensity of the DNA band was observed for
the rabbit anti-Egr1 antibody but not for normal rabbit IgG (Fig. 3).
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Fig. 3. Egr1 speciﬁcally interacts with the consensus EGR1-binding sequence within
the PER2 promoter. SH-SY5Y cells treated with 20 mM LiCl for 12 h were cross-linked,
lysed, and immunoprecipitated with anti-Egr1 antibody or normal rabbit IgG (negative
control). The precipitated DNA was subjected to PCR with primers speciﬁc for the
off-target region (−1891/−1701) or target region (−189/−36). One aliquot of input
DNA was used as a positive control.
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were left untreated or treated with 20 mM LiCl for 8 h and the luciferase activity was me
in triplicate (*, P b 0.05, n = 9).3.5. Lithium stimulates EGR1 expression in RA-SH-SY5Y cells
Next, we investigated whether lithium regulates EGR1 expression
in RA-SH-SY5Y cells. Serum-starved cells were treated with 20 mM
LiCl for different periods of time and the amount of EGR1 mRNA was
measured by Northern blotting. Upon lithium stimulation, accumula-
tion of EGR1 mRNA was detected within 0.5 h and the maximal level
was reached at 1 h, after which there was a rapid decrease to control
levels (Fig. 4A). To evaluate whether EGR1 mRNA expression with
lithium is caused by transcriptional activation, EGR1 promoter activity
was analyzed using a luciferase reporter. The EGR1 promoter con-
struct, pEgr1-Luc (−781/+1), was transfected into SH-SY5Y cells
and luciferase activity was measured. Upon lithium exposure, EGR1
promoter activities were signiﬁcantly elevated in a dose-dependent
manner (Fig. 4B), suggesting that lithium upregulates EGR1 expres-
sion at the transcriptional level. We also conﬁrmed the amount of
expressed EGR1 protein by Western blot analysis. The EGR1 protein
level was reached a maximum at approximately 3 h followed by a
gradual decrease, but readily detectable up to 12 h after lithium treat-
ment (Fig. 4C).
3.6. Knockdown of EGR1 attenuates lithium-induced PER2 expression
To conﬁrm the functional role of EGR1 in lithium-induced PER2
transcription, we depleted EGR1 using RNA interference. The knock-
down of EGR1 expression in SH-SY5Y cells by transient transfection of
shRNA plasmids generating EGR1-speciﬁc siRNA (pSilencer/siEgr1)
was assessed using Western blotting (Fig. 4D). We found that knock-
down of EGR1 expression reduced PER2 protein levels (Fig. 4E) and
the promoter activity (Fig. 4F) induced by lithium.EGR1
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1975S.H. Kim et al. / Biochimica et Biophysica Acta 1832 (2013) 1969–19793.7. Lithium-induced EGR1 expression is mediated byMAPK/ELK1 pathway
In many cell systems, activation of MAPKs, including the ERK, JNK,
and p38 MAPKs, mediates EGR1 expression [51–53]. To determine
whether MAPK pathways are activated by lithium in RA-SH-SY5Y
cells, serum-starved RA-SH-SY5Y cells were treated with lithium for
various lengths of time, and the activation status of MAPKs was
assessed using phospho-speciﬁc antibodies. The phosphorylation of
ERK1/2 increased rapidly within 15 min, while JNK and p38 MAPK
phosphorylation increased after 30 and 60 min, respectively, after
lithium treatment (Fig. 5A), suggesting that lithium stimulatedmultiple
MAPK signaling pathways. ELK1 is activated by ERK, JNK, and p38MAPK
[54], and complexedwith the serum response factor (SRF) on the serum
response element (SRE) within the EGR1 gene [55]. Activated ELK1
plays a crucial role in extracellular-signal-induced transcription of the
EGR1 gene [56]. We also observed that ELK1 phosphorylation was in-
creased in a time-dependent manner with lithium treatment (Fig. 5B).
To determine whether lithium stimulated ELK1 trans-acting activity,
we used a luciferase reporter assay system. SH-SY5Y cells were
cotransfected with the trans-acting plasmid Gal4-Elk1 and the pFR-Luc
reporter plasmid containing Gal4-binding sequences. Treatment with
lithium enhanced the trans-acting activity of Gal4-Elk1, which was
strongly inhibited in the presence of dn-ERK2, dn-JNK1, and dn-p38B
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Fig. 5. Effect of forced expression of dn-ERK, -JNK or -p38 kinase in lithium-induced Elk1 act
for various lengths of time. Total protein extracts were analyzed by Western blotting using
Tyr185), or phospho-p38 kinase (Thr180/Tyr182) antibody (A), or phospho-Elk1 (Ser38
cotransfected with 50 ng Elk1 trans-activator plasmid pFA/Gal4-Elk1 and 0.5 μg pFR-Luc
each), as indicated. Then, 48 h later, cells were treated with 20 mM LiCl for 8 h and their lu
periments, each performed in triplicate (*, P b 0.05, n = 9). (D) SH-SY5Y cells were cotrans
centrations of expression plasmid for Elk1, pCMV/ﬂagElk1. After 48 h, cells were treated
means ± SD of three independent experiments, each performed in triplicate (*, P b 0.05, n(Fig. 5C). Thus, ELK1 could be activated by all three major MAPKs in
lithium-treated SH-SY5Y cells. To determine whether lithium-induced
EGR1 expression is mediated by ELK1, we cotransfected an EGR1 pro-
moter construct and expression plasmid for ELK1. Transient transfection
of ELK1 enhanced lithium-induced EGR1 promoter activity (Fig. 5D).
Thus, lithium upregulates EGR1 expression via MAPK-dependent ELK1
transactivation.
3.8. The ERK pathway is necessary for lithium-induced EGR1 and
PER2 expression
To determine which MAPK was responsible for lithium-induced
EGR1 expression, SH-SY5Y cells were cotransfected with an EGR1 pro-
moter construct and expression plasmids with various mutant MAPK
constructs. Lithium-induced EGR1 promoter activity was reduced sig-
niﬁcantly by transient transfection with dn-ERK2 or dn-JNK1, but not
by dn-p38 (Fig. 6A). To conﬁrm the role of MAPKs in lithium-induced
EGR1 expression, we used chemical inhibitors of the MAPKs. Similar
to the promoter assay, Western blot analysis showed inhibition of ERK
(U0126) and JNK (SP600125) inhibited lithium-induced accumulation
of EGR1 protein, whereas the p38 MAPK inhibitor SB203580 had no
effect (Fig. 6B). Meanwhile, the lithium-induced increase in PER2 pro-
moter activity (Fig. 6C) and PER2 protein level were blocked only byLu
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1976 S.H. Kim et al. / Biochimica et Biophysica Acta 1832 (2013) 1969–1979inhibition of the ERK MAPK pathway (Fig. 6D). These data suggest that
although all three major MAPK pathways are stimulated and involved
in ELK1 stimulation by lithium treatment, only the ERK/ELK1/EGR1
cascade is functionally linked to PER2 expression.
3.9. Lithium-induced PER2 expression is impaired in the Egr1−/− mouse
brain
To evaluate the involvement of EGR1 in lithium-induced PER2 expres-
sion in vivo, Egr1+/+ and Egr1−/−micewere i.p. injectedwith lithiumand
Per2 expression in the frontal cortex was analyzed. Real-time PCR analy-
sis showed that administration of lithium signiﬁcantly increased Egr1 and
Per2mRNA levels in the frontal cortex 2 h after drug delivery in Egr1+/+
mice, but not in Egr1−/−mice (P b 0.05; Fig. 7A). TheWestern blot anal-
ysis showed similar results (P b 0.05; Fig. 7B). These ﬁndings demon-
strate that lithium-induced Per2 expression is mediated by Egr1 in the
brain in vivo.
4. Discussion
We demonstrated that the mood stabilizer lithium induced PER2
expression via EGR1, activated by the ERK/ELK1 signaling pathway.
Lithium increased mRNA and protein levels of PER2 in differentiated
neuronal cells, and stimulated the transcription of the PER2 gene through
EGR1 cis-acting response elements within the proximal region of the
PER2 promoter. The induction of PER2 through EGR1 was mediated
through the ERK/ELK1 signal pathway. This was also found in the brain
in vivo. Lithium increased Per2 in the mouse frontal cortex, which wasLu
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Fig. 6. Requirement of ERK MAPK for lithium-induced EGR1 and PER2 expression. (A an
pPer2-Luc (−180/+50) (C), along with expression plasmid encoding dn-ERK2, dn-JNK1, o
LiCl for 8 h and their luciferase activities were measured. Data are the means ± SD of thr
D) RA-SH-SY5Y cells were pretreated with 5 μM U0126, 10 μM SP600125, or 10 μM SB2035
extracts were analyzed by Western blotting using an antibody against EGR1 (B) or PER2 anattenuated in Egr1−/−mice, compared to Egr1+/+mice. Taken together,
these results indicate that the mood stabilizer lithium regulates the
circadian gene PER2 via the ERK/ELK1/EGR1 signaling pathway in neu-
ronal cells.
Induction of PER2 by lithium has been reported previously under
several different experimental conditions. For example, lithium has
been shown to signiﬁcantly increase the expression of Per2 and Cry1
and prolong the period of Per2 in NIH3T3 cells [31], to lengthen the
period of Per2 in ﬁbroblasts and SCN tissues from PER2::LUC knock-
in mice [29,30,32], and to restore to neural Per2 expression in the
mouse brain that was blunted by chronic restraint stress [57]. In the
present study, we also found that lithium upregulates PER2 expression
in differentiated SH-SY5Y cells and mouse brain. Taken together, these
results suggest that PER2 could be a lithium-responsive target clock gene.
Although evidence about the effect of lithium on PER2 induction
has accumulated, the underlying mechanisms are not yet understood.
BMAL1 andCLOCK, orNPAS2, a forebrain analog of CLOCK [58], positively
regulate the transcription of PER2 through the E-box in the promoter
region [16]. However, in previous studies, a lithium-related increase in
Per2 expression was reported to occur without a preceding increase in
Clock or Bmal1 in serum-shocked NIH3T3 cells [31], and lithium did not
affect the Bmal1 promoter in a Bmal1::LUC reporter cell line [29]. Lithium
has been reported to induce a phase delay in Per2 expression and
increase Per2 protein levels in serum-shocked NIH3T3 cells and PER2:
LUC cells. Furthermore, the inhibitory action of lithium on GSK-3β has
been suggested to stimulate Per2 mRNA expression [29,30]. In the
present study, GSK-3β was not involved in lithium-induced PER2
expression in differentiated SH-SY5Y cells. In addition, activatingEGR1
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Fig. 7. Effect of lithium on mRNA and protein expression of Egr1 and Per2 in the frontal
cortex of Egr1−/− mice. (A and B) Lithium (150 mg/kg) was injected intraperitoneally
to control wild-type (Egr1+/+) or Egr1 KO mice (Egr1−/−). At 2 h after lithium injec-
tion, mRNA (A) and protein (B) levels of Egr1 and Per2 in the frontal cortex were mea-
sured with real-time PCR (A) and immunoblot analysis (B). mRNA levels are presented
as relative values to each control level. The immunoreactivity value was quantiﬁed and
presented as relative optical density (OD) to that of the control. Values are presented
as means ± SD. *, P b 0.05 (n = 4–6).
1977S.H. Kim et al. / Biochimica et Biophysica Acta 1832 (2013) 1969–1979transcription factor 4 (ATF4) and ATF2 positively regulate Per2
expression by binding to a cAMP-responsive element (CRE) [59,60].
In contrast, the bZIP transcription factor E4BP4 represses the transcrip-
tion of Per2 by binding to its promoter [61]. In the present study, we are
the ﬁrst to demonstrate that ERK pathway-mediated EGR1 positively
regulates PER2 transcription in response to lithium in differentiated
SH-SY5Y cells by directly binding to the promoter. Further studies
regarding the interactive mechanisms of PER2 transcription through
ERK-EGR1, cAMP-ATF, GSK-3β, and E4BP4 (aswell as possible differential
effects depending on cell type) are required.
Many previous reports have demonstrated phase advances of
circadian rhythms in mood disorders, including depressive disorder
and bipolar disorder [9,62], although the evidence regarding the
phase advance hypothesis of depressive disorder has not been con-
ﬁrmatory [63]. In addition, several reports have shown that lithium
lengthens the circadian period of behavioral rhythms [28,29,64].
The lithium-induced lengthening of behavioral rhythms is accom-
panied by a prolonged circadian period and increased oscillation
amplitude in Per2 [29] that is mediated by transcriptional activation
[29,32]. These ﬁndings suggest that the upregulation of Per2 transcrip-
tion may be related to the phase-delay effects of lithium on circadian
rhythm; however, this hypothesis requires further clariﬁcation.
EGR1 is abundantly expressed in the nervous system and activated
rapidly in response to various stimuli as an immediate early gene (IEG)
[65]. In the present study, lithium rapidly induced EGR1 in differentiated
SH-SY5Y cells and in the frontal cortex of the mouse brain. EGR1
encodes several functionally different products, such as transcription
factors, cytoskeletal proteins, kinases, phosphatases, and components
of the proteasomal and ubiquitination machinery [65–67]. Previous
studies have indicated that Egr1 also affects the transcription of circadi-
an genes. The Cry1 gene has an Egr1 response element in the promoter,
and Egr1 binds to its promoter and inhibits the transcription of Cry1 in
the pars tuberalis region of the anterior pituitary [68]. Egr1 is involved
in the induction of Per1 by GnRH in pituitary gonadotrope cells [69]. In
the present study, the PER2 gene was also found to have EGR1 binding
sequences in its promoter region, and EGR1 positively regulated PER2
transcription via the ERK/Elk1 signaling pathway.
IEGs including Egr1 are induced by photic stimuli in the SCN of
rats and mice [70–73] suggesting a role for Egr1 in phase shifting in
response to light stimuli. However, Egr1−/− mice entrain normally
to a 12-h light–dark cycle and have been shown to re-entrain locomotor
activity to phase advances and phase delays in the light cycle [74].
Although phase shifting of locomotor activity rhythm was not affected,
other physiological variables can be altered in Egr1−/− mice. As
discussed earlier, Egr1 has been reported to be involved in the tran-
scription of Cry1 [68], Per1 [69], and, as demonstrated in our study,
Per2. Egr1 is involved in the regulation of melatonin-sensitive genes,
including Cry1 and melatonin receptor 1 (mt1) [68]. An investigation
of the circadian parameters in Egr1−/−mice is necessary to extend the
current ﬁndings to various other circadian functions.
ERK1/2 is a major upstream kinase that induces EGR1 [53,65].
Lithium is known to increase ERK1/2 phosphorylation [37,47,75],
and the present ﬁndings were consistent with this. The PER2 gene
was shown to co-localize with p-ERK immunoreactivity in SCN cells
in response to gastrin-releasing peptide (GRP) [76], and Per2 induction
also co-occurredwith expressionof c-Fos, another IEG, in response to var-
ious stimuli, including photic stimuli and GRP [76–78]. ERK1/2 mediates
the expression of IEGs, including Egr1, c-Fos, and JunB, in the SCN in
response to photic stimuli as the ﬁrst step leading to the transcription
of various genes [79]. These data suggest a possible relationship between
the ERKpathway and the rapid inducibility of PER2. ERK is involved in the
regulation of circadian genes aswell as circadian behaviors. The activity of
ERK itself oscillates in the SCN as well as forebrain regions, including the
hippocampus [80,81]. The expressions of Per1 andCry1 are also related to
Erk1/2 activity [82–84]. The present study demonstrated that the
ERK/ELK1 signal pathway upregulates PER2 expression by inducingIEG EGR1 in differentiated SH-SY5Y cells and in vivo in the brain. Lithium,
as well as light, alters circadian genes via ERK pathway-dependent EGR1
induction.
Findings regarding the transcriptional regulation of Per2 via the
Erk/Elk1/Egr1 pathway were also conﬁrmed in vivo. The Per2 gene is
widely expressed in extra-hypothalamic areas of the brain [7,8,11].
Per2 is abundantly expressed in the frontal cortex and shows circadian
changes in gene expression [7,11]. Furthermore, in the frontal cortex,
Per2 has been localized in neurons [7]. Per2 plays important roles in
the initiation and resetting of the circadian clock system in the SCN of
the hypothalamus and other brain regions, including the frontal cortex
[7,85]. There has been a recent increase in reports of novel functions of
peripheral Per2 in behavioral regulation. For example, Per2 in forebrain
regions has been shown to be involved in behavioral responses such as
stress responses and fear memory [57,86,87]. The Per2 gene in cortical
regions of the brain has been shown to be involved in themanifestation
of locomotor activity rhythm in rats [6]. Furthermore, antidepressants,
including ﬂuoxetine and agomelatine [88,89], and addictive agents
such as morphine, alcohol, and cocaine [90–92] affect Per2 protein
levels in forebrain regions. Per2 is also known to affect cell proliferation,
acting as a tumor suppressor gene [3,93] and affecting neurogenesis in
1978 S.H. Kim et al. / Biochimica et Biophysica Acta 1832 (2013) 1969–1979the hippocampus [94]. However, its function in the brain outside of the
SCN, including the frontal cortex, requires further investigation. The
frontal cortex is a core region related to pathogenic and therapeutic
mechanisms ofmood disorders [95,96]. Behavioral and cellular implica-
tions of lithium-induced PER2 in neuronal cells and in frontal cortex
need to be investigated in future studies.
In summary, lithium induces PER2 gene expression in neuronally
differentiated SH-SY5Y cells and in vivo in the mouse brain through
EGR1, activated via the ERK signaling pathway. PER2 is not only a
core component of a circadian clock system but is also involved in
the regulation of behavioral manifestations, such as mood, anxiety,
locomotor activity, and cell proliferation. The present ﬁndings demon-
strate the mechanisms of lithium's effects on PER2 via EGR1, indicating
a connection between theMAPK-EGR1 pathway and the circadian gene
system in the mechanism of action of lithium.
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